Free Trial

Prima BioMed (IMMP) Competitors

Prima BioMed logo
$1.77 +0.13 (+7.93%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.73 -0.04 (-2.20%)
As of 08/22/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMMP vs. VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, AKBA, PHAR, and CRON

Should you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

Prima BioMed vs. Its Competitors

Prima BioMed (NASDAQ:IMMP) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Prima BioMed's average media sentiment score of 0.00 equaled Verve Therapeutics'average media sentiment score.

Company Overall Sentiment
Prima BioMed Neutral
Verve Therapeutics Neutral

Prima BioMed has higher earnings, but lower revenue than Verve Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prima BioMed$5.14M50.55-$28.01MN/AN/A
Verve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27

Prima BioMed presently has a consensus price target of $7.00, indicating a potential upside of 295.48%. Verve Therapeutics has a consensus price target of $14.57, indicating a potential upside of 30.92%. Given Prima BioMed's stronger consensus rating and higher probable upside, research analysts clearly believe Prima BioMed is more favorable than Verve Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prima BioMed
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verve Therapeutics
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Prima BioMed has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Prima BioMed has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Prima BioMed's return on equity of 0.00% beat Verve Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prima BioMedN/A N/A N/A
Verve Therapeutics -303.64%-35.81%-27.57%

Summary

Prima BioMed beats Verve Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMP vs. The Competition

MetricPrima BioMedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$240.73M$3.11B$5.75B$9.62B
Dividend YieldN/A2.23%4.40%4.10%
P/E RatioN/A21.1431.2526.05
Price / Sales50.55345.39433.91193.97
Price / CashN/A43.1937.7358.48
Price / Book1.698.129.536.61
Net Income-$28.01M-$54.72M$3.26B$265.65M
7 Day Performance2.31%2.62%2.13%2.03%
1 Month Performance5.36%2.68%2.80%-0.31%
1 Year Performance-27.16%10.93%30.68%19.06%

Prima BioMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMP
Prima BioMed
0.9963 of 5 stars
$1.77
+7.9%
$7.00
+295.5%
-26.3%$240.73M$5.14M0.002,021Positive News
Upcoming Earnings
Gap Up
VERV
Verve Therapeutics
2.975 of 5 stars
$11.13
flat
$14.57
+30.9%
N/A$992.13M$32.33M-5.27110
LENZ
LENZ Therapeutics
1.2609 of 5 stars
$38.77
+11.8%
$49.60
+27.9%
+80.0%$989.15MN/A-20.41110Gap Up
High Trading Volume
PRAX
Praxis Precision Medicines
1.71 of 5 stars
$44.95
-2.2%
$95.22
+111.8%
-2.0%$966.84M$8.55M-3.66110
RCUS
Arcus Biosciences
2.4061 of 5 stars
$9.19
+1.4%
$21.14
+130.2%
-40.6%$964.27M$258M-2.90500Positive News
AVXL
Anavex Life Sciences
3.8871 of 5 stars
$11.35
+2.4%
$44.00
+287.7%
+55.5%$946.42MN/A-20.6440Analyst Forecast
GPCR
Structure Therapeutics
2.6364 of 5 stars
$17.51
+7.4%
$75.71
+332.4%
-49.9%$939.42MN/A-16.68136News Coverage
SYRE
Spyre Therapeutics
2.8888 of 5 stars
$15.25
+0.6%
$53.40
+250.2%
-29.8%$915.68M$890K-4.4973Analyst Upgrade
AKBA
Akebia Therapeutics
4.0034 of 5 stars
$3.35
-2.0%
$6.75
+101.5%
+117.0%$906.80M$160.18M-19.70430Positive News
Analyst Revision
PHAR
Pharming Group
2.3827 of 5 stars
$12.10
-8.5%
$30.00
+147.9%
+72.3%$906.45M$297.20M-93.08280High Trading Volume
CRON
Cronos Group
0.7375 of 5 stars
$2.67
+16.1%
N/A+12.6%$882.76M$117.61M53.40450Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:IMMP) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners